The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review.

BACKGROUND

High-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) have been used for the treatment of COPD and respiratory failure in clinical settings. We aimed to evaluate the efficacy and safety of HFNC therapy in patients with COPD and type II respiratory failure, to provide evidence to the clinical COPD management.

METHODS

We searched Cochrane et al. databases up to Dec 31, 2020 for randomized controlled trials (RCTs) on the use of HFNC therapy in patients with COPD and type II respiratory failure. Two researchers independently screened the literature according to the inclusion and exclusion criteria, and evaluated the quality of the literature and extracted data. We used Revman5.3 software for statistical analysis of collected data.

RESULTS

A total of 6 RCTs involving 525 COPD and type II respiratory failure patients. Meta-analyses indicated that compared with NIV, HFNC could significantly reduce PaCO level (MD = - 2.64, 95% CI (- 3.12 to - 2.15)), length of hospital stay ((MD = - 1.19, 95 CI (- 2.23 to - 0.05)), the incidence of nasal facial skin breakdown ((OR = 0.11, 95% CI (0.03-0.41)). And there were no significant differences between the two groups in PaO ((MD = 2.92, 95% CI (- 0.05 to 5.90)), incidence of tracheal intubation ((OR = 0.74, 95% CI (0.34-1.59)) and mortality (OR = 0.77, 95% CI (0.28-2.11)).

CONCLUSIONS

HFNC is more advantageous over NIV in the treatment of COPD and type II respiratory failure. Future studies with larger sample size and strict design are needed to further elucidate the role of HFNC in COPD and respiratory failure.